For Immediate Release
For more information, contact:
Mike Shefky, Communications and Marketing Manager
mshefky@sitcancer.org ~ (414) 271-2456 ~ www.sitcancer.org
ISBTC WORKSHOP EXAMINES STATE OF THE SCIENCE AND BARRIERS TO THE CLINICAL TRANSLATION OF NEW COMBINATION THERAPIES FOR CANCER
Milwaukee--The International Society for Biological Therapy of Cancer's (sitc) "Workshop on Future Opportunities for Combination Biological Therapy of Cancer" was held on November 1 in Boston, Massachusetts. The Workshop was attended by over 200 delegates consisting of both basic scientists and clinical investigators from academia, industry and regulatory agencies from the U.S. and Europe. This important program brought leading investigators in the field together to examine key opportunities for translating new combination therapies in the field of oncology. In addition, meeting participants discussed critical issues that must be addressed to enable sustained and rapid progress in the development of combination therapies using cancer biologics. Summary documents outlining the potential opportunities and obstacles for clinical translation of novel combination therapies will be published in the near future.
"This exciting program brought together key stakeholders from academia, industry and regulatory agencies in the U.S. and Europe to engage in essential dialogue regarding key scientific opportunities in the clinical development of combination therapies using cancer biologics, as well as the central challenges that may limit our progress in the field," says Workshop Co-Organizer and sitc President Jon M. Wigginton, MD. "The Workshop addressed what has become a major strategic consideration for the field of oncology and highlighted the commitment of the sitc in playing a leadership role in this area."
sitc's next scheduled workshop will be the "Workshop on Inflammation in Cancer Development" to be held on October 30, 2008 in San Diego, California. This highly interactive program will assemble thought-leaders in the field to discuss the current "state of the science" and recent progress in understanding the relationship between inflammation and the pathophysiology of cancer. Program chairs will include Steven Dubinett, MD (University of California Los Angeles) and George Weiner, MD (University of Iowa).
Founded in 1984, the International Society for Biological Therapy of Cancer (sitc) is a not for profit organization of clinicians, researchers, students, post-doctoral fellows, and allied health professionals dedicated to improving cancer patient outcomes by advancing the development and application of biological therapy through interaction, innovation and leadership.
###
